
Avinger AVGR
Quarterly report 2024-Q3
added 11-07-2024
Avinger Gross Profit 2011-2026 | AVGR
Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.
Calculation formula:Importance for business:
Gross Profit = Revenue – Cost of Goods Sold (COGS)
Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
- Raw materials and supplies
- Wages of production personnel
- Depreciation of equipment
- Transportation and warehousing costs (if directly related to production)
- Assessing core business profitability
If gross profit is declining, it may indicate rising production costs or falling sales. - Financial planning
Gross profit is the basis for calculating other key metrics, such as operating and net profit. - Benchmarking against competitors
Gross profit analysis helps compare the efficiency of different companies within the same industry. - Insights into pricing effectiveness
If gross profit is low, the company may be pricing too low or failing to control costs effectively.
- Increase in raw material and supply costs
- Rising production expenses
- Price reductions due to competition
- Decrease in sales volume
- Currency exchange rate fluctuations (for imports/exports)
Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.
Annual Gross Profit Avinger
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2 M | 2.65 M | 3.42 M | 2.62 M | 2.87 M | 1.38 M | -3.07 M | 4.77 M | 4.24 M | 4.7 M | 4.76 M | 4.41 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 4.77 M | -3.07 M | 2.9 M |
Quarterly Gross Profit Avinger
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 426 K | 378 K | 343 K | - | 388 K | 605 K | 636 K | - | 790 K | 657 K | 524 K | - | 800 K | 1.02 M | 894 K | - | 777 K | 359 K | 501 K | - | 847 K | 720 K | 373 K | - | 543 K | -111 K | 394 K | - | -1.2 M | -1.46 M | -584 K | 981 K | 1.57 M | 1.04 M | 1.18 M | 1.05 M | 971 K | 1.41 M | 800 K | 1.5 M | 1.16 M | 1.42 M | 616 K | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.57 M | -1.46 M | 620 K |
Gross Profit of other stocks in the Medical devices industry
| Issuer | Gross Profit | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Abiomed
ABMD
|
690 M | - | - | $ 17.2 B | ||
|
Allied Healthcare Products
AHPI
|
443 K | - | 3.58 % | $ 2.21 M | ||
|
Alphatec Holdings
ATEC
|
424 M | $ 20.67 | -1.76 % | $ 2.95 B | ||
|
Acutus Medical
AFIB
|
-3.14 M | - | -26.83 % | $ 2.62 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
67.9 M | - | - | $ 1.77 B | ||
|
Apyx Medical Corporation
APYX
|
33.8 M | $ 3.52 | 0.57 % | $ 122 M | ||
|
Cognyte Software Ltd.
CGNT
|
247 M | $ 8.91 | -5.21 % | $ 640 M | ||
|
Boston Scientific Corporation
BSX
|
11.5 B | $ 94.77 | -0.63 % | $ 139 B | ||
|
Obalon Therapeutics, Inc.
OBLN
|
584 K | - | -5.86 % | $ 30.6 M | ||
|
Bio-Rad Laboratories
BIO
|
342 M | $ 304.72 | 0.42 % | $ 8.6 B | ||
|
Apollo Endosurgery
APEN
|
42.4 M | - | - | $ 475 M | ||
|
Conformis
CFMS
|
23.2 M | - | - | $ 16.4 M | ||
|
Cardiovascular Systems
CSII
|
173 M | - | 0.15 % | $ 844 M | ||
|
Cutera
CUTR
|
-12.7 M | - | -10.19 % | $ 1.99 M | ||
|
BioSig Technologies
BSGM
|
229 K | - | 37.08 % | $ 85.7 M | ||
|
Electromed
ELMD
|
50 M | $ 27.78 | -4.4 % | $ 235 M | ||
|
Bruker Corporation
BRKR
|
1.65 B | $ 47.97 | 1.83 % | $ 7.15 K | ||
|
Eargo
EAR
|
14.3 M | - | - | $ 10.2 M | ||
|
Abbott Laboratories
ABT
|
18.7 B | $ 124.11 | -0.94 % | $ 216 B | ||
|
EDAP TMS S.A.
EDAP
|
26.6 M | $ 3.31 | 0.61 % | $ 123 M | ||
|
Second Sight Medical Products
EYES
|
500 K | - | -0.97 % | $ 54.4 M | ||
|
CryoLife, Inc.
CRY
|
168 M | - | -4.14 % | $ 702 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.25 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
28.7 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
43.7 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
1.99 M | - | - | $ 111 M | ||
|
IRadimed Corporation
IRMD
|
56.3 M | $ 95.52 | -1.81 % | $ 1.21 B | ||
|
Dynatronics Corporation
DYNT
|
6.01 M | - | 14.99 % | $ 929 K | ||
|
Intersect ENT, Inc.
XENT
|
50.2 M | - | - | $ 955 M | ||
|
InMode Ltd.
INMD
|
317 M | $ 14.91 | 1.46 % | $ 1.18 B | ||
|
LivaNova PLC
LIVN
|
871 M | $ 60.9 | -1.02 % | $ 3.3 B | ||
|
LENSAR
LNSR
|
14.1 M | $ 11.68 | 0.43 % | $ 135 M | ||
|
Align Technology
ALGN
|
2.8 B | $ 156.64 | 0.31 % | $ 11.7 B | ||
|
Accuray Incorporated
ARAY
|
147 M | $ 0.85 | 3.09 % | $ 87.4 M | ||
|
ClearPoint Neuro
CLPT
|
19.1 M | $ 14.01 | 2.41 % | $ 379 M | ||
|
FONAR Corporation
FONR
|
42.4 M | $ 18.52 | -0.24 % | $ 121 M | ||
|
AxoGen
AXGN
|
142 M | $ 30.97 | -5.38 % | $ 1.37 B | ||
|
Axonics Modulation Technologies
AXNX
|
198 M | - | - | $ 3.31 B | ||
|
GBS
GBS
|
1.25 M | - | -0.57 % | $ 7.12 M | ||
|
IRIDEX Corporation
IRIX
|
21.8 M | $ 1.18 | 3.51 % | $ 19 M | ||
|
CONMED Corporation
CNMD
|
733 M | $ 40.83 | 0.62 % | $ 1.26 B | ||
|
OrthoPediatrics Corp.
KIDS
|
149 M | $ 17.7 | -0.32 % | $ 408 M | ||
|
Globus Medical
GMED
|
719 M | $ 87.03 | -0.39 % | $ 11.8 B | ||
|
Integra LifeSciences Holdings Corporation
IART
|
953 M | $ 12.02 | -3.22 % | $ 926 M | ||
|
Aziyo Biologics
AZYO
|
11.1 M | - | 1.37 % | $ 20.5 M | ||
|
Myomo
MYO
|
10.3 M | $ 0.96 | 3.31 % | $ 6.77 M |